about
Mitochondrial DNA haplogroup D4a is a marker for extreme longevity in JapanSYK is a critical regulator of FLT3 in acute myeloid leukemiaThe genomic landscape of pediatric Ewing sarcoma.Ovarian cancer detection by logical analysis of proteomic data.A robust meta-classification strategy for cancer detection from MS data.Robust diagnosis of non-Hodgkin lymphoma phenotypes validated on gene expression data from different laboratories.Breast cancer prognosis by combinatorial analysis of gene expression data.Breast cancer stratification from analysis of micro-array data of micro-dissected specimens.A computational approach to predicting cell growth on polymeric biomaterials.Portraits of breast cancer progression.Hoxa9 and Meis1 Cooperatively Induce Addiction to Syk Signaling by Suppressing miR-146a in Acute Myeloid LeukemiaIdentifying mRNA targets of microRNA dysregulated in cancer: with application to clear cell Renal Cell Carcinoma.Triplication of a 21q22 region contributes to B cell transformation through HMGN1 overexpression and loss of histone H3 Lys27 trimethylation.The intersection of genetic and chemical genomic screens identifies GSK-3α as a target in human acute myeloid leukemia.Lactase persistence and lipid pathway selection in the MaasaiFunctional, chemical genomic, and super-enhancer screening identify sensitivity to cyclin D1/CDK4 pathway inhibition in Ewing sarcoma.Identification of the YES1 Kinase as a Therapeutic Target in Basal-Like Breast CancersLong noncoding RNA EWSAT1-mediated gene repression facilitates Ewing sarcoma oncogenesis.Tight regulation of memory CD8(+) T cells limits their effectiveness during sustained high viral loadIncreased SYK activity is associated with unfavorable outcome among patients with acute myeloid leukemiaTargeting MYCN in neuroblastoma by BET bromodomain inhibitionTargeting MTHFD2 in acute myeloid leukemiaIn Vivo RNAi screening identifies a leukemia-specific dependence on integrin beta 3 signalingTransforming growth factor-beta signaling: emerging stem cell target in metastatic breast cancer?Carcinoma-associated fibroblast-like differentiation of human mesenchymal stem cellsThe creatine kinase pathway is a metabolic vulnerability in EVI1-positive acute myeloid leukemia.Antigen availability determines CD8⁺ T cell-dendritic cell interaction kinetics and memory fate decisionsCharacterizing genomic alterations in cancer by complementary functional associations.High expression of lymphocyte-associated genes in node-negative HER2+ breast cancers correlates with lower recurrence rates.Identification of a microRNA panel for clear-cell kidney cancer.Origin and differentiation of human memory CD8 T cells after vaccination.TOX Regulates Growth, DNA Repair, and Genomic Instability in T-cell Acute Lymphoblastic Leukemia.Constructing near-perfect phylogenies with multiple homoplasy events.Synergistic Drug Combinations with a CDK4/6 Inhibitor in T-cell Acute Lymphoblastic Leukemia.Bepridil exhibits anti-leukemic activity associated with NOTCH1 pathway inhibition in chronic lymphocytic leukemia.Exploiting an Asp-Glu "switch" in glycogen synthase kinase 3 to design paralog-selective inhibitors for use in acute myeloid leukemia.KLF5 controls glutathione metabolism to suppress p190-BCR-ABL+ B-cell lymphoblastic leukemiaGenome-scale CRISPR-Cas9 screen identifies druggable dependencies in wild-type Ewing sarcomaResistance Mechanisms to SYK Inhibition in Acute Myeloid LeukemiaHigh-throughput Chemical Screening Identifies Focal Adhesion Kinase and Aurora Kinase B Inhibition as a Synergistic Treatment Combination in Ewing Sarcoma
P50
Q21562568-F255D855-5ED7-4FEC-88E4-FA9EED93D634Q24337247-1CF4E08A-4EF9-486B-B9B3-E01F66EFD7EDQ27853063-63B18264-3AE3-46EF-BF0D-A217147FC3D3Q30909733-6350A0F1-4B2F-4FFB-AAC0-BFD3A043F726Q31024840-478CA6EB-B3E4-48E3-9F3F-84C1BF4A2C9BQ31026873-47954E87-5753-4C82-8DE9-324C6E8D1294Q31049486-6A65B800-B573-48E6-A12B-34F9AC1163E4Q31158856-C9EDBBFB-D020-4310-9223-9C58AF99EA55Q33211972-C995EB4D-F481-4D7A-AF80-F428433E036BQ33293454-A06BD16F-F8DE-4A25-AAAB-6E455F8AFF5EQ33558976-69C35105-944B-416A-82AB-45B3748F3116Q33565049-C0491EE6-3515-4EEC-AD66-9552B416D022Q33691942-5BE21E13-553B-4797-AD28-4214AFF1B6D8Q34156754-ED84684B-49A1-4A08-BE55-1F67C5C829F2Q34427355-0CFF1BB6-EC54-48FE-8127-50CEB4B4561CQ34492346-ABDAAFE7-E928-4A76-BEF0-9F9E3E80C33CQ34972623-3E646866-8265-4094-AE8C-11F0C7816F90Q35145374-8CC110CD-8575-4941-81EB-76040D575DFCQ35621976-A47E5731-FC45-41B1-9737-33C42B3E3DE2Q36413237-FA9B10CC-9A3D-4697-BA2A-81A472C38E0FQ36903802-3D1D79A7-3A7F-4B94-899A-BB93A189D1B1Q37047306-C83CE038-CA9A-4715-9C18-B6AE89097F22Q37101484-5FB1AC7D-1ACE-4D46-BD8A-566F3087D529Q37219226-879EB930-87A6-47C6-82DE-A011A02EB819Q39976240-3F5A8C9F-F245-407B-8FAE-520233759B42Q41213085-82137411-EE24-41F6-9052-B1CC9C372972Q41916666-EC1D46D1-3C9A-492F-8D02-1B2D1789790BQ42219637-7FCA8BA2-C149-4928-B906-752A4AA7AB21Q42521534-95B4CA56-94C1-42D0-8F1E-AC50FC73B014Q45714425-81EC2CA5-D158-4F1F-8C7E-1BB707860B55Q46925820-F2FCF59C-1563-4495-819C-2F4C1EEE2FC9Q47704064-03543850-45C4-4AE0-931E-877BFCFD440DQ48437378-AA88B5CE-E28C-4498-A42D-7A8A9ADF1AE2Q50285730-812FA6C5-DA9B-4CF0-A5D4-A40F2892346CQ51765546-43535941-8F87-42EF-9C67-EA8E16EA032AQ52668632-666329A8-AA71-4560-AFED-704F4B834F3CQ58585276-870BC952-C60E-48D9-934C-63F801316477Q61570969-A7B3DD85-1B8D-4DF4-86A5-02ED7510EDADQ91472490-645B5BE0-6622-4EF2-8209-DFE6BDD68983Q93064614-9C9CF33D-129F-4C8F-97F5-E7B98E5CF295
P50
description
researcher ORCID ID = 0000-0002-5668-6297
@en
wetenschapper
@nl
name
Gabriela Alexe
@ast
Gabriela Alexe
@en
Gabriela Alexe
@es
Gabriela Alexe
@nl
type
label
Gabriela Alexe
@ast
Gabriela Alexe
@en
Gabriela Alexe
@es
Gabriela Alexe
@nl
prefLabel
Gabriela Alexe
@ast
Gabriela Alexe
@en
Gabriela Alexe
@es
Gabriela Alexe
@nl
P21
P31
P496
0000-0002-5668-6297